The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies

Haematologica. 2017 Oct;102(10):e400-e403. doi: 10.3324/haematol.2017.169334. Epub 2017 Jun 22.

Authors

Josée Golay¹, Greta Ubiali², Martino Introna²

Affiliations

¹ Center of Cellular Therapy "G. Lanzani, USC Hematology, and Fondazione per la Ricerca Ospedale Maggiore, ASST Papa Giovanni XXIII, Bergamo, Italy [email protected].
² Center of Cellular Therapy "G. Lanzani, USC Hematology, and Fondazione per la Ricerca Ospedale Maggiore, ASST Papa Giovanni XXIII, Bergamo, Italy.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies / drug effects*
Antigens, CD20 / immunology*
Benzamides / pharmacology*
Benzamides / therapeutic use
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Protein Kinase Inhibitors / therapeutic use
Protein-Tyrosine Kinases / antagonists & inhibitors
Pyrazines / pharmacology*
Pyrazines / therapeutic use

Substances

Antibodies
Antigens, CD20
Benzamides
Protein Kinase Inhibitors
Pyrazines
Protein-Tyrosine Kinases
acalabrutinib